This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 17126 results found since Jan 2013.
Ig Nobel Prizes honor zombie spiders, rock-licking scientists, and a clever commode
Why do scientists lick rocks? The answer is disappointingly sensible, says Jan Zalasiewicz, a geologist at the University of Leicester. Mineral particles within rocks stand out better on a wet surface than on a dry one, so licking makes rocks easier to identify in the field. And Zalasiewicz waxes nostalgic for the days when scientists did more than just lick rocks—they cooked and, in some cases,
actually ate the materials they studied
, he noted in a 2017 essay written for the Paleontological Association’s newsletter. “We’ve lost the art of recognizing rocks by taste,” he laments.
For the creative...
Source: Science of Aging Knowledge Environment - September 14, 2023 Category: Geriatrics Source Type: research
Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
J Dermatolog Treat. 2023 Dec;34(1):2256905. doi: 10.1080/09546634.2023.2256905.NO ABSTRACTPMID:37705359 | DOI:10.1080/09546634.2023.2256905
Source: Journal of Dermatological Treatment - September 14, 2023 Category: Dermatology Authors: Carlo Alberto Vignoli Luigi Gargiulo Federica Sanna Alessandra Narcisi Antonio Costanzo Source Type: research
Correction to: Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the U.K. and Denmark, and to: Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark
Br J Dermatol. 2023 Sep 14:ljad338. doi: 10.1093/bjd/ljad338. Online ahead of print.NO ABSTRACTPMID:37708291 | DOI:10.1093/bjd/ljad338
Source: The British Journal of Dermatology - September 14, 2023 Category: Dermatology Source Type: research
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
CONCLUSIONS: These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.PMID:37708254 | DOI:10.1093/bjd/ljad253
Source: The British Journal of Dermatology - September 14, 2023 Category: Dermatology Authors: Brett King Jerry Shapiro Manabu Ohyama Alexander Egeberg Bianca Maria Piraccini Brittany Craiglow Rodney Sinclair Yun-Fei Chen Wen-Shuo Wu Yuxin Ding Najwa Somani Yves Dutronc Source Type: research
Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
J Dermatolog Treat. 2023 Dec;34(1):2256905. doi: 10.1080/09546634.2023.2256905.NO ABSTRACTPMID:37705359 | DOI:10.1080/09546634.2023.2256905
Source: Journal of Dermatological Treatment - September 14, 2023 Category: Dermatology Authors: Carlo Alberto Vignoli Luigi Gargiulo Federica Sanna Alessandra Narcisi Antonio Costanzo Source Type: research
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
ConclusionDistinct and clinically relevant hair loss profiles were identified in ALLEGRO-2b/3 participants. Ritlecitinib was efficacious compared with placebo, independent of hair loss profile at baseline.Trial registrationClinicalTrials.gov identifier, NCT03732807.Graphical abstract
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study
ConclusionIn conclusion, we reported prevalence of post-COVID hair fall that was confirmed by trichoscopy and which affected approximately 61.4% of infected females.
Source: Irish Journal of Medical Science - September 14, 2023 Category: General Medicine Source Type: research
First Patient Dosed in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
WALTHAM, Mass. and DUBLIN, Sept. 13, 2023. Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been...
Source: Drugs.com - Clinical Trials - September 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Anxiety and Depression in Patients with Alopecia Areata in Eskisehir, Turkey
CONCLUSION: Depression and anxiety were more prevalent in patients with AA than in healthy volunteers. Dermatologists should keep in mind psychiatric diseases such as depression and anxiety that may accompany patients diagnosed with AA.PMID:37701059 | PMC:PMC10494858 | DOI:10.2147/CCID.S424374
Source: Clinical, Cosmetic and Investigational Dermatology - September 13, 2023 Category: Dermatology Authors: Hamza Yildiz Serkan Zincir Source Type: research
